AWARENESS OF LIPID GUIDELINE RECOMMENDATIONS FOR HIGH-RISK PATIENTS AMONGST PRIMARY CARE PHYSICIANS IN CANADA

Abstract

BackgroundLipid guidelines for cardiovascular (CV) risk reduction have evolved in recent years, particularly since the introduction of PCSK9 inhibitors. In many jurisdictions, CV risk management is provided by primary care physicians (PCPs). We surveyed Canadian PCPs regarding their awareness and implementation of the 2021 Canadian Cardiovascular Society (CCS) lipid guideline recommendations for patients following an acute coronary syndrome (ACS) or for those with diabetes but without CV disease.Methods and ResultsFrom a national database of PCPs with interest and/or experience in CV medicine, we invited PCPs to complete a survey regarding lipid management in high-risk patients. A committee of PCPs and specialists with lipid expertise including several co-authors of the 2021 CCS lipid guidelines had designed the survey to probe awareness and practice patterns. A total of 250 PCPs from across Canada completed the survey between January and April 2022. 23.6% of respondents had previously prescribed a PCSK9 inhibitor. Almost all (97.2%) PCPs concurred that a post-ACS patient should be seen by their PCP within 4 weeks of hospital discharge (81.2% within 2 weeks). Almost half (44.4%) responded that discharge summaries provided inadequate information relevant for PCPs, and 41.6% felt that lipid management post-ACS was the primary responsibility of specialists. More than half (58.4%) articulated challenges when seeing a post-ACS patient, related to inadequate discharge information, complexities of polypharmacy and duration of therapies, and managing perceived or real statin intolerance. 63.2% correctly identified the LDL-C intensification threshold of 1.8 mmol/L in post-ACS patients, while 81.4% considered that PCSK9 inhibitors were indicated only for those patients who were already receiving statins plus ezetimibe or who had substantially elevated LDL-C levels. 53.6% were able to correctly identify clinical features associated with greatest absolute benefit of PCSK9 inhibitors in post-ACS patients. For patients with diabetes but without ASCVD, 81.2% of PCPs incorrectly believed that PCSK9 inhibitors were indicated for LDL-C levels above threshold despite statin therapy, and only 43.6% correctly identified the LDL-C threshold for treatment intensification of 2.0 mmol/L.ConclusionWhile PCPs are aware of the urgency regarding lipid management in post-ACS patients, many encounter challenges after hospital discharge, frequently deferring lipid management to specialists. Thus, one year following publication of the 2021 CCS lipid guidelines, substantial knowledge gaps remain regarding intensification thresholds and treatment options for patients post-ACS or for those with diabetes. Innovative and effective knowledge translation programs are urgently required. BackgroundLipid guidelines for cardiovascular (CV) risk reduction have evolved in recent years, particularly since the introduction of PCSK9 inhibitors. In many jurisdictions, CV risk management is provided by primary care physicians (PCPs). We surveyed Canadian PCPs regarding their awareness and implementation of the 2021 Canadian Cardiovascular Society (CCS) lipid guideline recommendations for patients following an acute coronary syndrome (ACS) or for those with diabetes but without CV disease. Lipid guidelines for cardiovascular (CV) risk reduction have evolved in recent years, particularly since the introduction of PCSK9 inhibitors. In many jurisdictions, CV risk management is provided by primary care physicians (PCPs). We surveyed Canadian PCPs regarding their awareness and implementation of the 2021 Canadian Cardiovascular Society (CCS) lipid guideline recommendations for patients following an acute coronary syndrome (ACS) or for those with diabetes but without CV disease. Methods and ResultsFrom a national database of PCPs with interest and/or experience in CV medicine, we invited PCPs to complete a survey regarding lipid management in high-risk patients. A committee of PCPs and specialists with lipid expertise including several co-authors of the 2021 CCS lipid guidelines had designed the survey to probe awareness and practice patterns. A total of 250 PCPs from across Canada completed the survey between January and April 2022. 23.6% of respondents had previously prescribed a PCSK9 inhibitor. Almost all (97.2%) PCPs concurred that a post-ACS patient should be seen by their PCP within 4 weeks of hospital discharge (81.2% within 2 weeks). Almost half (44.4%) responded that discharge summaries provided inadequate information relevant for PCPs, and 41.6% felt that lipid management post-ACS was the primary responsibility of specialists. More than half (58.4%) articulated challenges when seeing a post-ACS patient, related to inadequate discharge information, complexities of polypharmacy and duration of therapies, and managing perceived or real statin intolerance. 63.2% correctly identified the LDL-C intensification threshold of 1.8 mmol/L in post-ACS patients, while 81.4% considered that PCSK9 inhibitors were indicated only for those patients who were already receiving statins plus ezetimibe or who had substantially elevated LDL-C levels. 53.6% were able to correctly identify clinical features associated with greatest absolute benefit of PCSK9 inhibitors in post-ACS patients. For patients with diabetes but without ASCVD, 81.2% of PCPs incorrectly believed that PCSK9 inhibitors were indicated for LDL-C levels above threshold despite statin therapy, and only 43.6% correctly identified the LDL-C threshold for treatment intensification of 2.0 mmol/L. From a national database of PCPs with interest and/or experience in CV medicine, we invited PCPs to complete a survey regarding lipid management in high-risk patients. A committee of PCPs and specialists with lipid expertise including several co-authors of the 2021 CCS lipid guidelines had designed the survey to probe awareness and practice patterns. A total of 250 PCPs from across Canada completed the survey between January and April 2022. 23.6% of respondents had previously prescribed a PCSK9 inhibitor. Almost all (97.2%) PCPs concurred that a post-ACS patient should be seen by their PCP within 4 weeks of hospital discharge (81.2% within 2 weeks). Almost half (44.4%) responded that discharge summaries provided inadequate information relevant for PCPs, and 41.6% felt that lipid management post-ACS was the primary responsibility of specialists. More than half (58.4%) articulated challenges when seeing a post-ACS patient, related to inadequate discharge information, complexities of polypharmacy and duration of therapies, and managing perceived or real statin intolerance. 63.2% correctly identified the LDL-C intensification threshold of 1.8 mmol/L in post-ACS patients, while 81.4% considered that PCSK9 inhibitors were indicated only for those patients who were already receiving statins plus ezetimibe or who had substantially elevated LDL-C levels. 53.6% were able to correctly identify clinical features associated with greatest absolute benefit of PCSK9 inhibitors in post-ACS patients. For patients with diabetes but without ASCVD, 81.2% of PCPs incorrectly believed that PCSK9 inhibitors were indicated for LDL-C levels above threshold despite statin therapy, and only 43.6% correctly identified the LDL-C threshold for treatment intensification of 2.0 mmol/L. ConclusionWhile PCPs are aware of the urgency regarding lipid management in post-ACS patients, many encounter challenges after hospital discharge, frequently deferring lipid management to specialists. Thus, one year following publication of the 2021 CCS lipid guidelines, substantial knowledge gaps remain regarding intensification thresholds and treatment options for patients post-ACS or for those with diabetes. Innovative and effective knowledge translation programs are urgently required. While PCPs are aware of the urgency regarding lipid management in post-ACS patients, many encounter challenges after hospital discharge, frequently deferring lipid management to specialists. Thus, one year following publication of the 2021 CCS lipid guidelines, substantial knowledge gaps remain regarding intensification thresholds and treatment options for patients post-ACS or for those with diabetes. Innovative and effective knowledge translation programs are urgently required.